{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"61.4","value":"157"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"title":"Cycle 1 Day 1 (20 mg/m²)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"112","value":"153"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"title":"Cycle 2 Day 1 (27 mg/m²)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Systemic clearance is a measure of the ability of the body to eliminate drug, expressed in units of volume per time.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received carfilzomib administered by intravenous (IV) infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (20 mg/m² on days 1 and 2 of cycle 1 and 27 mg/m² thereafter). Participants also received 20 mg dexamethasone IV or orally on days 1, 2, 8, 9, 15, 16, 22, and 23.\n\nParticipants received treatment until disease progression, unacceptable toxicity, initiation of new antimyeloma therapy, withdrawal of consent, subject noncompliance, or intercurrent illness or worsening of a chronic condition, whichever occurred first.","id":"OG000","title":"Carfilzomib With Dexamethasone"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic analyses were conducted on a subset of participants at selected sites. Results are reported for participants in the PK analysis population with available data at each time point. PK profiles with a coefficient of determination (R²; goodness of fit) \\< 0.8 or percent extrapolated AUC \\> 20% were excluded from the analysis.","reportingStatus":"POSTED","timeFrame":"Cycles 1 and 2, day 1 at predose, 5 minutes after the start of carfilzomib infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of infusion.","title":"Systemic Clearance (CL) of Carfilzomib After Intravenous Infusion","type":"SECONDARY","unitOfMeasure":"L/hr"}